Hormone Therapy Use Differentially Associated With Breast Cancer Subtypes
July 16th 2025Estrogen-progestin hormone therapy used to manage menopausal symptoms and other women’s health conditions is associated with a higher risk of developing luminal-like breast cancer subtypes and other subtypes.
Read More
MFN Drug Pricing: Risks to Access, Affordability, and Innovation in Health Care
July 16th 2025Adam Colborn, JD, associate vice president of congressional affairs at AMCP, shares insights on the impact of the Most Favored Nation drug pricing order when it comes to access, affordability, and innovations in US health care.
Read More
Chronic Rhinosinusitis With Nasal Polyps and Asthma: Understanding the Connection and Treatment Gaps
July 15th 2025Chronic rhinosinusitis with nasal polyps increases the likelihood of developing coexisting conditions, such as asthma, underscoring the need for more effective, comprehensive treatments.
Read More
For Community Oncology, Good News in PFS Offset by Potential Wreckage of MFP Proposal
July 15th 2025CMS proposes the 2026 Physician Fee Schedule (PFS), addressing payment disparities in oncology, but the community oncology community warns of financial threats from the Inflation Reduction Act. Updates reflect late Tuesday release of the proposed 2026 schedule for the Hospital Outpatient Prospective Payment System.
Read More
Dupilumab Shows Strong Efficacy in SCORAD-Based AD Assessment
July 14th 2025With few real-life studies that have specifically focused on how atopic dermatitis (AD) affects patients living with the chronic inflammatory skin condition in Latin American countries, the present authors investigated dupilumab-related outcomes among 100 patients using SCORing Atopic Dermatitis (SCORAD) index values.
Read More
The Future of Drug Pricing: Most Favored Nation, PBMs, and Patient Access
July 11th 2025During the Reshaping Rx: Navigating 2025 Drug Pricing Policies webinar, panelists discussed the Most Favored Nation executive order, bills aimed at pharmacy benefit managers (PBMs), and other drug pricing policies.
Read More